2026 payer coverage update — GLP-1 formulary changes by insurer
Pinned because it affects plans people have already made, not because it is dramatic. Everything below is what is confirmed as of today.
This post is the record, and it will be edited as things change — with the change noted rather than substituted. If you have something firmer than what is here, a document or a date or a first-hand account, post it and it goes in with credit.
Read it this way:
Nothing here is advice about your situation, and the situation is still moving.
InsuranceTom said:2026 payer coverage update — GLP-1 formulary changes by insurer Pinned because it affects plans people have already made, not because it is dramatic.
Agreed, and coverage criteria are plan-specific rather than insurer-specific. Two people with the same insurer and different employers have different rules, which is why "my insurer covers it" is not transferable information.
InsuranceTom said:2026 payer coverage update — GLP-1 formulary changes by insurer Pinned because it affects plans people have already made, not because it is dramatic.
This is where I part company with the consensus forming above. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThis one has a reasonably settled answer, so here it is. Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.
Correct me if the detail matters more than I have assumed.
TrialTracker_MD said:Agreed, and coverage criteria are plan-specific rather than insurer-specific.
Mine went the same way, slower.